Forum Review

The Many Flavors of Hyperhomocyst(e)inemia: Insights from Transgenic and Inhibitor-Based Mouse Models of Disrupted One-Carbon Metabolism

C. LEE ELMORE1 and ROWENA G. MATTHEWS1,2

ABSTRACT

Mouse models that perturb homocysteine metabolism, including genetic mouse models that result in deficiencies of methylenetetrahydrofolate reductase, methionine synthase, methionine synthase reductase, and cystathionine β-synthase, and a pharmaceutically induced mouse model with a transient deficiency in betaine-homocysteine methyl transferase, have now been characterized and can be compared. Although each of these enzyme deficiencies is associated with moderate to severe hyperhomocyst(e)inemia, the broader metabolic profiles are profoundly different. In particular, the various models differ in the degree to which tissue ratios of S-adenosylmethionine to S-adenosylhomocysteine are reduced in the face of elevated plasma homocyst(e)ine, and in the distribution of the tissue folate pools. These different metabolic profiles illustrate the potential complexities of hyperhomocyst(e)inemia in humans and suggest that comparison of the disease phenotypes of the various mouse models may be extremely useful in dissecting the underlying risk factors associated with human hyperhomocyst(e)inemia. Antioxid. Redox Signal. 9, 1911–1921.

INTRODUCTION

Hyperhomocyst(e)inemia has been correlated with increased risk for cardiovascular disease ([5] and references cited therein), development of Alzheimer disease (6, 36, 56), neural tube defects (39, 51, 59, 60), and other adverse pregnancy outcomes including congenital cardiac defects (26, 51, 57, 69), preeclampsia (11, 44–46), and orofacial clefts (70). It is now well established that administration of folic acid results in significant reduction of plasma total homocyst(e)ine (2, 47, 64, 67), but the results of several large folate therapy clinical trials to reduce the progression of cardiovascular disease have been disappointing (1, 12, 31, 34, 43, 64), although showing promise in others (48, 53, 58). These findings argue against the hypothesis that homocysteine itself is the causative agent of disease, per se. To address this dilemma, it has been proposed that hyperhomocyst(e)inemia may merely be a marker for these disease processes, unrelated to the etiology of disease. However, we also need to consider an alternate hypothesis: that hyperhomocyst(e)inemia can result from a number of different genetic and physiological conditions (e.g., dietary, disease-related, or clinically induced) and that the associated pathologies will be directly linked to the particular conditions giving rise to the elevation in plasma total homocyst(e)ine in the first place.

In considering this alternate hypothesis, the various transgenic mouse models for hyperhomocyst(e)inemia are particularly useful, because the detailed metabolite measurements that are possible in the mouse serve to illustrate the very different profiles of hyperhomocyst(e)inemia that are possible in mammals and may suggest possible approaches to treating human conditions. Each of these mouse genes has a known orthologous human counterpart, believed to play an identical role. Interestingly, each of these genes specifies an enzyme that uses a vitamin-derived cofactor or substrate/product or both, and methionine itself is an essential amino acid, so that diet becomes

1Life Sciences Institute and 2Dept. of Biological Chemistry, University of Michigan, Ann Arbor, Michigan.
an important factor in the development and progression of disease. Four transgenic mouse models involve disruption of genes specifying enzymes directly involved in homocysteine metabolism: methylenetetrahydrofolate reductase (4), cystathionine β-synthase (68), methionine synthase (61), and methionine synthase reductase (13). A final mouse model created a transient deficiency in betaine-homocysteine methyltransferase induced by the inhibitor S-(6-carboxybutyl)-DL-homocysteine (7). Figure 1 shows the reactions catalyzed by each of these enzymes and places them in perspective in mammalian one-carbon metabolism.

Methylenetetrahydrofolate reductase catalyzes the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, and the mammalian enzyme uses electrons derived from NADPH for this reduction (Fig. 2). The electrons flow from NADPH to the flavin adenine dinucleotide cofactor of the enzyme, and thence from the reduced flavin to methylenetetrahydrofolate. This reaction, which is irreversible in vivo (20), commits tetrahydrofolate-bound one-carbon units to use in the remethylation of homocysteine to form methionine and removes them from the pool of one-carbon units that are used for de novo purine and thymidylate biosynthesis. The enzyme is allosterically regulated by the ratio of S-adenosylmethionine (AdoMet) to S-adenosylhomocysteine (AdoHcy) in the cell (25, 30); AdoMet inhibits the enzyme, whereas AdoHcy competes with AdoMet but does not affect enzyme activity.

Cobalamin-dependent methionine synthase catalyzes the next step in the regeneration of the methyl group of methionine (Fig. 3). In the course of this overall reaction, the methyl group of methyltetrahydrofolate is transferred to the cobalamin cofactor to form methylcobalamin and tetrahydrofolate and then from methylcobalamin to homocysteine to form methionine and to regenerate the cobalamin cofactor in the highly reduced cob(II)alamin form (Fig. 4). The cob(II)alamin form of the enzyme is susceptible to oxidation, and about once in every thousand turnovers, forms an inactive cob(III)alamin species. Return of this inactive species to the catalytic cycle requires reduction of cob(II)alamin to cob(I)alamin and remethylation. In mammals, the electron needed for reduction is supplied by methionine synthase reductase, a dual flavoprotein with one flavin adenine dinucleotide and one flavin mononucleotide cofactor (32, 41). The flavin adenine dinucleotide cofactor of methionine synthase reductase accepts electrons from NADPH. The methyl group for reactivation of methionine synthase is supplied by AdoMet, rather than by methyltetrahydrofolate. AdoMet binds to the C-terminal activation domain of methionine synthase. Either dietary deficiency in cobalamin or impaired methionine

**FIG. 1. Overview of mammalian one-carbon metabolism.** Four genetic mouse models involving disruptions of enzymes in this pathway have been highlighted in grey, as has betaine-homocysteine methyltransferase, where transient enzyme deficiencies have been induced by treatment of mice with an inhibitor. BHMT, betaine-homocysteine methyltransferase; CBS, cystathionine β-synthase; CGL, cystathionine γ-lyase; DHFR, dihydrofolate reductase; DMGD, dimethylglycine dehydrogenase; GNMT, glycine N-methyltransferase; MAT, methionine adenosyltransferase; MS, cobalamin-dependent methionine synthase; MSR, methionine synthase reductase; MTHFR, methylenetetrahydrofolate reductase; MTs, AdoMet-dependent methyltransferases; SAHH, S-adenosylhomocysteine hydrolase; SDH, sarcosine dehydrogenase; SHMT, serine hydroxymethyltransferase; TS, thymidylate synthase.
Methionine synthase and methionine synthase reductase are ubiquitously expressed, and in many cells, they catalyze the only pathway for the regeneration of the methyl group of methionine. However, in some tissues, an alternative pathway for remethylation of methionine is catalyzed by betaine-homocysteine methyltransferase (Fig. 5) (37). This enzyme uses betaine, a derivative formed from the metabolism of choline and also present in the diet, as the methyl donor to homocysteine, and does not require methyltetrahydrofolate. Its distribution is limited; the enzyme is abundant in human liver and kidney, but absent in heart and brain.

Homocysteine is generated as a result of biologic methylation reactions that use AdoMet as a methyl donor (see Fig. 1). When excess dietary methionine is present, homocysteine can be converted to cystathionine by cystathionine β-synthase (Fig. 6); cystathionine is then broken down to form cysteine by cystathionine γ-lyase. In humans with cystathionine β-synthase deficiency, severe hyperhomocysteinemia and homocystinuria develop, and their intracellular [AdoMet]/[AdoHcy] ratios are dramatically reduced because of the accumulation of AdoHcy in their tissues.

In this review, we compare the metabolic and physiologic profiles associated with hyperhomocysteinemia in each of the five mouse models, pointing out where further experiments might be informative, and we discuss their relevance to human disease. We begin with a brief discussion of the published literature on each of these five mouse models.

**Cystathionine β-synthase**

Homozygous cystathionine β-synthase deficiency in humans leads to extreme hyperhomocysteinemia and elevated plasma methionine. Homozygotes also develop skeletal abnormalities, dislocation of the ocular lens, and thromboembolic disease (40).

Heterozygotes typically have metabolite levels that overlap with those of controls and are generally asymptomatic.

The first transgenic mouse model of hyperhomocyst(e)inemia to be developed was a targeted disruption of the Cbs gene specifying cystathionine β-synthase (68). The disruption led to a complete absence of cystathionine β-synthase activity in Cbs<sup>−/−</sup> mice. Nonetheless, matings of Cbs<sup>+/+</sup> pairs resulted in the mendelian 1:2:1 distribution of wild-type:heterozygous:homozygous genotypes; thus, deficiencies of cystathionine β-synthase are not associated with embryonic lethality. However, Cbs<sup>−/−</sup> animals exhibited ~80% mortality during the third and fourth weeks postpartum. Before 2 weeks of age, when viability becomes an issue, Cbs<sup>−/−</sup> animals showed decreased glutathione concentrations in liver and brain tissues. Cysteine concentrations were also low in liver and brain tissues and in kidneys of males (66). Whereas surviving homozygous males are able to reproduce, female homozygotes are infertile (68).

Because of the high mortality in Cbs<sup>−/−</sup> mice, most studies have been conducted with heterozygotes. In Cbs<sup>+/−</sup> mice derived from matings of heterozygotes, plasma total homocysteine levels were found to be elevated 2.5-fold over those in Cbs<sup>+/+</sup> littersmates at 7 weeks, and 1.5-fold at 15 weeks in mice fed a standard laboratory chow. At 15 weeks, plasma methionine levels were elevated 1.3-fold in Cbs<sup>+/−</sup> versus wild-type mice, whereas total plasma folate levels were unaffected. Levels of AdoHcy were elevated ~1.3-fold in the liver of Cbs<sup>+/−</sup>, whereas the AdoMet levels were the same. Similar results were observed in Cbs<sup>+/−</sup> brain, although the decrease in the [AdoMet]/[AdoHcy] ratio was somewhat more pronounced (9).

Many physiological studies have been conducted on cystathionine β-synthase heterozygotes fed high methionine–low folate or methyl-deficient diets, but for the purposes of comparison with other mouse models of hyperhomocyst(e)inemia, this review focuses on those studies performed with mice fed...
Methylenetetrahydrofolate reductase

The most common genetic cause of mild human hyperhomocyst(e)inemia is the 677C>T mutation in the MTHFR gene specifying methylenetetrahydrofolate reductase (24). Patients with severe methylenetetrahydrofolate reductase deficiency exhibit homocystinuria and hyperhomocyst(e)inemia, but to a much lesser degree than patients with complete cystathionine β-synthase deficiency. Plasma methionine levels are uniformly low. A decreased proportion of their intracellular folate is present as methyltetrahydrofolate (19). The clinical severity associated with severe deficiency is variable and may be manifested as developmental delay and motor and gait abnormalities. They do not exhibit megaloblastic anemia (50).

A transgenic mouse model of hyperhomocyst(e)inemia induced by methylenetetrahydrofolate reductase disruption was developed in Rima Rozen’s laboratory (4). Her mouse strain incorporated a targeted disruption of the Mthfr gene. When heterozygous Mthfr-deleted mice are mated, the offspring show the Mendelian distribution at 6 days, indicating that neither the heterozygous nor the homozygous genotype results in increased embryonic lethality (4). However, significant postnatal mortality of homozygotes is found, with 83% dying at an average age of 9 days postpartum (54).

Mthfr homozygous null mice completely lacked methylenetetrahydrofolate reductase activity in all tissues, whereas in Mthfr heterozygotes, the measured activity was 60–70% of that found in wild-type littermates. Body weights of the surviving homozygotes were ~80% those of wild-type littermates at 2 weeks, but at later times, the surviving homozygotes showed nearly normal body weight. Plasma total homocyst(e)ine concentrations in Mthfr<sup>−/−</sup> mice were ~10 times those of wild-type littermates, whereas Mthfr heterozygotes had about twice wild-type levels. The livers of surviving 3-week-old Mthfr<sup>−/−</sup> mice showed severe fatty infiltration of the liver with microvesicular lipid droplets (steatosis), whereas liver pathology was absent from Mthfr<sup>+/−</sup> littermates.

Plasma total homocyst(e)ine was 3.2 μM in Mthfr<sup>+/+</sup>, 5.3 μM in Mthfr<sup>+/−</sup>, and 32 μM in Mthfr<sup>−/−</sup> mice at 5 weeks of age (4). AdoMet levels were lower in all tissues examined in Mthfr<sup>−/−</sup> mice than in their wild-type littermates, and AdoHcy levels were significantly elevated, resulting in [AdoMet]/
[AdoHcy] ratios that were sharply decreased (4). In agreement with this finding, DNA hypomethylation was observed in all tissues analyzed (4).

Methylenetetrahydrofolate reductase converts methylenetetrahydrofolate to methyltetrahydrofolate, the only ubiquitous one-carbon donor for the remethylation of homocysteine to form methionine in mammals (see Fig. 5). In homozygotes, the lack of methylenetetrahydrofolate reductase activity results in severe depletion of methyltetrahydrofolate pools, especially in liver (4). The residual methyltetrahydrofolate is presumably derived from the diet.

Mthfr heterozygotes develop normally and appear outwardly healthy. In contrast, Mthfr homozygous mutants exhibit developmental delays, and their body weights are significantly lower than those of their wild-type littermates throughout the first postpartum 5 weeks. Many of the homozygous Mthfr-null mice that will later die prematurely show protrusive eyes, facial abnormalities, and shorter tails. Some show a “kinked” tail, a feature also seen in the curly-tail (ct) mouse, a model for neural tube defects. In contrast to female Cbs-null mice, the majority of surviving Mthfr homozygotes could reproduce. Homozygous Mthfr-deleted mice also exhibit lipid accumulation in the aorta, although the lesions are not typical of the advanced atherosclerotic lesions seen in, for example, the apoE knockout mouse.

Betaine-homocysteine methyltransferase provides an alternate route for remethylation of homocysteine, independent of methylenetetrahydrofolate. The enzyme is located primarily in liver and kidney. Betaine supplementation of the dams during gestation dramatically decreases neonatal mortality of Mthfr nullizygotes, from 83% to 26% (54). Offspring of betaine-supplemented dams also show decreased levels of homocysteine in both liver and brain, increased methionine, and more normal [AdoMet]/[AdoHcy] ratios. Cerebellar abnormalities are also ameliorated by betaine supplementation, although the cerebellum was still smaller than in wild-type littermates, and its architecture showed remaining abnormalities. These observations suggest that much of the pathology associated with Mthfr deficiency is the result of defective remethylation. Withdrawal of betaine supplementation after weaning had no effect on the survival of the nullizygotes, suggesting that the most critical need for remethylation may be in the first few weeks after birth.

**Methionine synthase**

Severe deficiency of methionine synthase (MTR, the cbtG genetic complementation group) is very rare in humans. Patients typically are seen in the first few months of life with vomiting, poor feeding, and lethargy. They show severe neurologic dysfunction, megaloblastic anemia and homocystinuria, or homocyst(e)inemia, or a combination of these, sometimes accompanied by hypomethioninemia (15).

A targeted deletion of the methionine synthase gene in mice results in embryonic lethality in Mtr-deleted homozgygotes (61). The authors suggested that embryos implant normally, as judged by the appearance of homozgygous embryos undergoing resorption at embryonic day 8.5 (E8.5). Supplementation of the dams with folic acid, folinic acid, and/or methionine and choline failed to rescue the phenotype. The authors suggest that the lethality is the result of methyl trapping in the embryo (i.e., the accumulation of methylenetetrahydrofolate at the expense of methylenetetrahydrofolate and 10-formyltetrahydrofolate in the absence of a functional methionine synthase). Because embryonic death occurs before the development of the placenta, they hypothesize that maternal-to-fetal transfer of folinic acid is insufficient to meet the needs of the developing embryo. The authors also demonstrated that methionine synthase is probably expressed in wild-type embryos by day E9.5, as judged by detection of methionine synthase mRNA.

The phenotype of Mtr+/− mice is relatively mild (10, 61). Mtr heterozygotes have ~60% of the methionine synthase activity measured in wild-type littermates. Plasma total homocyst(e)ine is mildly elevated, and plasma methionine concentrations are normal (10) or slightly elevated (61). Liver total folates are the same in wild-type and heterozygous animals fed a control diet, liver AdoHcy levels are decreased ~10% in the heterozygotes compared with the wild-type animals, and AdoMet levels are increased ~1.3-fold. In brain, AdoMet levels are the same in both genotypes within experimental error, whereas AdoHcy levels are slightly lower in the Mtr+/− mice. Although the authors did not emphasize these somewhat surprising metabolite levels, which did not reach statistical significance, similar results are seen in a mouse with a partial deficiency of methionine synthase reductase (see later).

In mice fed a standard laboratory chow, Mtr heterozygotes did not show any difference in relaxation of aortic rings in response to acetylcholine or nitroprusside, but higher levels of superoxide were detected in sections of heterozygotic cerebral arterioles by using the oxidative fluorescent dye dihydroethidium (10). The evidence for oxidative stress in mice that have little or no elevation in plasma total homocyst(e)ine is somewhat surprising, and the authors hypothesize that methyl trapping and the resultant redistribution of folate species might be related to the observed oxidative stress in cerebral vessels. However, this study did not directly examine folate distributions.
**Methionine synthase reductase**

Humans with severe methionine synthase reductase deficiency (MTRR, the cb/E genetic complementation group) show symptoms that are very similar to those with severe methionine synthase deficiency (15).

Preliminary studies of a mouse model with a targeted disruption of the Mtrr gene specifying methionine synthase reductase indicated that a complete lack of methionine synthase reductase also results in embryonic lethality [unpublished data of Roy Gravel, cited in (13)]. A mouse model in which the Mtrr gene was interrupted by a gene-trap insertion has been constructed (Mtrr<sup>Gt(GfT1Lx)XG334Byf</sup>; hereafter abbreviated Mtrr<sup>(G)</sup>) (13). Intercross mating of Mtrr<sup>(+/G)</sup> mice resulted in the mendelian distribution of offspring, and tissue-specific skipping of the gene trap’s cryptic exon was shown, leading to the presence of some wild-type Mtrr mRNA in Mtrr<sup>(G/G)</sup> mice. Levels of wild-type mRNA in homozygotes ranged from 37% in brain tissue to 0.8% in heart tissue, and specific activities of methionine synthase reductase were significantly lower in Mtrr<sup>(G/G)</sup> than in wild-type animals.

Mtrr<sup>(+/G)</sup> mice developed normally and showed only slightly elevated plasma total homocyst(e)ine and mildly decreased plasma methionine concentrations (13). Mtrr<sup>(G/G)</sup> males gained weight more slowly than their wild-type littersmates, whereas female homozygotes gained weight normally. Mtrr<sup>(G/G)</sup> animals also showed a four-fold elevation in plasma total homocyst(e)ine and a 35% decrease in plasma methionine. These values indicate that the Mtrr<sup>(G/G)</sup> mice are more severely affected than the Mtrr<sup>(+/-)</sup> mice. Despite elevated plasma total homocyst(e)ine and decreased plasma methionine, Mtrr<sup>(G/G)</sup> mice show normal to elevated intracellular AdoMet and reduced to normal intracellular AdoHcy, except in heart tissue. The [AdoMet]/[AdoHcy] ratio measured in the livers of wild-type Mtrr mice was 0.9, whereas that in the Mtrr<sup>(G/G)</sup> mice was 2.4. Both of these measurements were made in mice that had been fasted overnight to eliminate variability related to dietary intake of methionine.

Although total folate pool sizes in the liver, kidney, and heart of Mtrr<sup>(G/G)</sup> animals were the same as in their wild-type littersmates, a trend was noted toward increases in the contribution of methyltetrahydrofolate to the pool. Although not statistically significant, these observations suggest that mild methyl trapping may be occurring in these animals (13).

The gene-trap insertion containing a β-galactosidase–neomycin phosphotransferase gene fusion permits staining of Mtrr<sup>(+/G)</sup> embryos for β-galactosidase activity driven by the Mtrr promoter. At E9.5, a stage of development at which the neural tube is closing, the reporter is ubiquitously expressed, with particularly high levels in neural tissues, including the optic eminence, forebrain, midbrain, the second and fourth rhombomeres of the hindbrain, and the neural tube (32).

**Betaine-homocysteine methyltransferase**

We are not aware of any published studies on humans with a betaine-homocysteine methyltransferase deficiency.

A transgenic mouse model for betaine-homocysteine methyltransferase (BHMT) has not yet been constructed. However, transient BHMT deficiency can be induced in wild-type mice by injection of the BHMT inhibitor S-(β-carboxybutyl)-DL-homocysteine (7). These injections lead to 87% lower BHMT activity and a 2.7-fold increase in plasma total homocyst(e)ine. After repeated injections, the liver [AdoMet]/[AdoHcy] ratio was reduced.

**Table 1. Metabolite Concentrations in Plasma and Liver Tissue of Mouse Models for Hyperhomocyst(e)inemia**

<table>
<thead>
<tr>
<th>Mouse model genotype/treatment</th>
<th>Ref.</th>
<th>Hcy (μM)</th>
<th>Met (μM)</th>
<th>AdoMet (nmol/g liver)</th>
<th>AdoHcy (nmol/g liver)</th>
<th>[AdoMet]/[AdoHcy]</th>
<th>5-MethylTHF (% liver folates)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mtrr</td>
<td>13</td>
<td>4.6 ± 0.8</td>
<td>59.4 ± 7.4</td>
<td>45.9 ± 4.5</td>
<td>60.6 ± 8.3</td>
<td>0.9 ± 0.2</td>
<td>27 ± 4</td>
</tr>
<tr>
<td>+/+</td>
<td></td>
<td>5.5 ± 1.8</td>
<td>48.9 ± 10.5</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>+/Gt</td>
<td>61</td>
<td>18.4 ± 5.5</td>
<td>40.4 ± 6.6</td>
<td>64.1 ± 6.4</td>
<td>30.7 ± 4.7</td>
<td>2.9 ± 0.6</td>
<td>34 ± 10</td>
</tr>
<tr>
<td>Gu/Gt</td>
<td>9</td>
<td>4.1</td>
<td>78</td>
<td>33.1 ± 4.7</td>
<td>22.4 ± 2.2</td>
<td>1.5 ± 0.2</td>
<td>ND</td>
</tr>
<tr>
<td>+/−</td>
<td>6.1</td>
<td>102</td>
<td>42.1 ± 4.4</td>
<td>20.2 ± 2.2</td>
<td>2.3 ± 0.3</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>−/−</td>
<td></td>
<td>19.0 ± 0.7</td>
<td>55.4 ± 0.9</td>
<td>0.3</td>
<td>0.9 ± 1.3</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Mtrfr</td>
<td>4</td>
<td>3.3 ± 0.1</td>
<td>ND</td>
<td>27.7 ± 0.3</td>
<td>13.8 ± 0.3</td>
<td>2.0</td>
<td>23 ± 12</td>
</tr>
<tr>
<td>+/+</td>
<td></td>
<td>5.3 ± 0.8</td>
<td>ND</td>
<td>36.3 ± 0.7</td>
<td>36.3 ± 0.5</td>
<td>1.0</td>
<td>13 ± 6</td>
</tr>
<tr>
<td>+/−</td>
<td></td>
<td>32.3 ± 5.5</td>
<td>ND</td>
<td>19.0 ± 0.7</td>
<td>15.1 ± 1.5</td>
<td>1.1</td>
<td>ND</td>
</tr>
<tr>
<td>−/−</td>
<td></td>
<td>203.6 ± 65.3</td>
<td>ND</td>
<td>42.9 ± 8.8</td>
<td>27.4 ± 2.9</td>
<td>1.7 ± 0.2</td>
<td>ND</td>
</tr>
<tr>
<td>Cbs</td>
<td>68</td>
<td>6.1 ± 0.8</td>
<td>22.8 ± 1.6</td>
<td>42.9 ± 8.8</td>
<td>27.4 ± 2.9</td>
<td>1.7 ± 0.2</td>
<td>ND</td>
</tr>
<tr>
<td>+/+</td>
<td></td>
<td>3.5 ± 3.2</td>
<td>30.6 ± 2.5</td>
<td>41.9 ± 3.1</td>
<td>45.7 ± 5.1</td>
<td>1.0 ± 0.1</td>
<td>ND</td>
</tr>
<tr>
<td>+/−</td>
<td></td>
<td>203.6 ± 65.3</td>
<td>ND</td>
<td>5.5 ± 0.9</td>
<td>19.4 ± 1.1</td>
<td>0.4</td>
<td>ND</td>
</tr>
<tr>
<td>BHMT</td>
<td>7</td>
<td>2.3 ± 0.2</td>
<td>ND</td>
<td>16.4 ± 2.0</td>
<td>15.1 ± 1.5</td>
<td>1.1</td>
<td>ND</td>
</tr>
<tr>
<td>−CBHcy</td>
<td></td>
<td>18.5 ± 1.0</td>
<td>ND</td>
<td>8.1 ± 0.9</td>
<td>19.4 ± 1.1</td>
<td>0.4</td>
<td>ND</td>
</tr>
</tbody>
</table>
FIG. 7. Reaction catalyzed by glycine \(N\)-methyltransferase.

**DISCUSSION**

Table 1 provides a comparison of the metabolite levels associated with the different mouse models for hyperhomocyst(e)inemia. It is important to bear in mind that the absolute values may not be strictly comparable, both because different methods and standards were used in different studies, and because of differences in the protocols (e.g., in some studies, animals were fasted overnight before sample collection, whereas in others, they were not). Despite these caveats, comparisons of the wild-type mouse values with those of the heterozygous and homozygous mutant mice (or treated mice in the case of betaine-homocysteine methyltransferase) are informative. In the section that follows, we attempt to relate the very different metabolite profiles of these mouse models with some of the phenotypes associated with hyperhomocyst(e)inemia in mice and humans.

**Embryonic lethality**

Of the five mouse models for hyperhomocyst(e)inemia discussed here, only two, those due to deficiencies in methionine synthase or methionine synthase reductase, cause embryonic lethality. In such cases, the metabolism of the dam is unable to sustain the viability of the embryo, suggesting that these enzymes are required for embryonic survival. In the case of methionine synthase deficiency, lethality occurs before day E8.5, indicating that the embryo dies before the placental circulation becomes fully functional, starting at day E9.5 (61). The unique feature of both the methionine synthase and the methionine synthase reductase mouse models is that the associated enzyme deficiency is thought to lead to methyl trapping, or the accumulation of intracellular methyltetrahydrofolate at the expense of 10-formyltetrahydrofolate and methylenetetrahydrofolate. Mild methyl trapping is likely in the gene-trap model for methionine synthase reductase deficiency (13). It is well established that deficiencies in formyltetrahydrofolate and methylenetetrahydrofolate are associated with the apoptosis of rapidly growing cells in the adult (29), and it is plausible that they are also associated with the embryonic lethality, although this remains to be established rigorously. During the early stages of development, the growing embryo must rely primarily on folate stores deposited in the egg by the mother, and subsequently on exchange of nutrients with the mother through the yolk sac. It is plausible that yolk sac–mediated exchange becomes more and more limiting as the embryo grows in size, reaching a critical juncture just before the initiation of placental exchange, at a time when the neural tube is closing. The ability of the embryo to rebalance folate stores in response to metabolic demands may be essential for viability during this critical period. Embryos lacking methionine synthase or methionine synthase reductase may be particularly sensitive to folate pool imbalances.

Other mouse models for hyperhomocyst(e)inemia due to perturbations of one-carbon metabolism are associated with a deficiency rather than an excess of intracellular methyltetrahydrofolate (e.g., \(Mthfr\) deficiency) or are likely to have no effect on folate pool distribution (\(Cbs\) or \(Blmmt\)). Thus, hyperhomocyst(e)inemia in and of itself is not likely to be responsible for the embryonic lethality observed in mice with severe deficiencies in methionine synthase activity.

Embryonic lethality also is observed in mice with defective folate transport. Deficiencies in the folate-binding protein 1 (\(Folbp1\)) (42) or the reduced-folate carrier (\(Rfc\)) (35) lead to embryonic death by day E10. Supplementation of the \(Folbp1\) dams with folic acid reverses this phenotype but leads to a high incidence of neural tube defects in \(Folbp1^{-/-}\) embryos (63), whereas supplementation of the \(Rfc\) dams with high levels of folic acid partially prevents the embryonic lethality associated with \(Rfc\) deficiency (73). The embryonic lethality due to \(Rfc\) deficiency has been shown to be associated with impaired hematopoiesis (73).

It is of considerable interest that impaired folate transport and deficiencies of methionine synthase or methionine synthase reductase may be associated with embryonic lethality, whereas deficiencies of methylenetetrahydrofolate reductase are not. Although it might be thought that folate deficiency would affect all components of the folate pool equally, studies on the in vitro catalytic properties of the enzymes that compete for methyl donors have suggested that methylenetetrahydrofolate reductase has a much lower Michaelis constant (\(K_m\)) for this substrate than do thymidylate synthase or methylenetetrahydrofolate dehydrogenase (21), which would be expected to result in methyl trapping. Thus, embryos with folate deficiency and those with reduced methionine synthase activity may share a propensity for apoptosis due to insufficient supplies of 10-formyltetrahydrofolate and methylenetetrahydrofolate.

**Postnatal mortality**

In \(Mthfr\)-deficient mice and those lacking cystathionine \(\beta\)-synthase, homozygous mutants are born at the normal frequency from heterozygote matings, indicating that the dam can compensate for the absence of the enzyme in the fetus. However, in both cases, postnatal mortality is severe over the first few weeks. Homozygous mutants in both these models exhibit severe hyperhomocyst(e)inemia and methylation defects stemming from the lowered [AdoMet]/[AdoHcy] ratios in their tissues. The greatly reduced postnatal mortality of homozygous \(Mthfr\)-deficient pups seen when the dams are supplemented with betaine until weaning is a strong indication that the mortality is directly related to the inability to recycle homocysteine to methionine. Betaine supplementation does not appear to have been attempted to reduce the postnatal mortality in the cystathionine \(\beta\)-synthase–deficient mouse, but supplementation of
heterozygotes with betaine produced marked decreases in plasma total homocyst(e)ine (55).

Deficient methylation

DNA hypomethylation has been demonstrated in methylenetetrahydrofolate reductase–deficient and cystathionine β-synthase–deficient mice with decreased intracellular [AdoMet]/[AdoHcy] ratios. It might have been anticipated that methylation defects would also be observed in those mouse models that have impaired methionine synthase activity, caused either by deficiencies in methionine synthase or methionine synthase reductase, or dietary deficiency of cobalamin, the cofactor for methionine synthase, or possibly riboflavin, the precursor for the flavin mononucleotide and flavin adenine dinucleotide methionine synthase, or possibly riboflavin, the precursor for details. Containing a large amount of glycine N-methyltransferase activity, which normally serves to convert excess AdoMet to AdoHcy by methylation of glycine to produce sarcosine (see Fig. 7). Tissues like liver that contain high levels of glycine N-methyltransferase typically exhibit lower [AdoMet]/[AdoHcy] ratios than do tissues like heart that lack this enzyme (27, 72). In a wild-type mouse after overnight fasting, the [AdoMet]/[AdoHcy] ratio was 0.9 in liver and 47 in heart (13). Glycine N-methyltransferase activity is inhibited by methyltetrahydrofolate and activated by AdoMet (71). Thus, in an Mthfr-deficient mouse, with extremely low levels of methyltetrahydrofolate, glycine N-methyltransferase should be maximally active in the liver, whereas in a methionine synthase reductase–deficient mouse or a methionine synthase-deficient mouse, glycine N-methyltransferase would be expected to be substantially inhibited in liver, resulting in a sparing of the [AdoMet]/[AdoHcy] ratio, and perhaps, in the case of methyl trapping, even leading to an increase in the [AdoMet]/[AdoHcy] ratio.

Methylation defects would be expected in all tissues of methylenetetrahydrofolate reductase–deficient and cystathionine β-synthase–deficient mice, but only in tissues lacking glycine N-methyltransferase in the methionine synthase–deficient and methionine synthase reductase–deficient mouse. We would expect cobalamin deficiency to induce similar effects in rodents, although to our knowledge, the results of such studies have not yet been published.

Endothelial dysfunction and cardiovascular disease

Endothelial dysfunction has been proposed to represent a condition predisposing those affected to the development of cardiovascular disease and is often used as a surrogate for more expensive long-term studies on the incidence of cardiovascular disease in mouse models. The cerebral microcirculation appears to be particularly susceptible to endothelial dysfunction during hyperhomocyst(e)inemia (10). Among the techniques used to demonstrate endothelial dysfunction are measurements of relaxation of aortic rings or cerebral arterioles in response to administration of acetylcholine or nitroprusside (10), detection of superoxide in sections of vessels by using a fluorescent dye (10), and measurements of thrombomodulin activity (9). Evidence for endothelial dysfunction in the cerebral arterioles has been demonstrated in Cbs+/− mice with mild cystathionine β-synthase deficiency (9, 33), in heterozygotic Mthfr mice (65), and in heterozygotic Mtr mice (10). The degree of dysfunction was correlated with the level of plasma total homocyst(e)ine, regardless of the combination of genetic and dietary factors used to induce elevated homocyst(e)ine (14). Thus, endothelial dysfunction may be a consequence of the elevation in plasma total homocyst(e)ine itself, rather than resulting from indirect sequelae of the condition giving rise to hyperhomocyst(e)inemia.

We look forward to long-term studies on the incidence of cardiovascular disease in various mouse models to establish that endothelial dysfunction is a good surrogate.

Neural tube defects

Failure of the embryonic neural tube to close results in neural tube defects, including spina bifida and anencephalus. In humans, ~70% of these devastating malformations can be prevented by periconceptual folate supplementation of the mother (38). However, plasma folate and red cell folate levels in pregnant women who later have an infant with a neural tube defect, although lower than those in controls, are in the normal range for the majority of affected mothers (8). Homocyst(e)ine levels in early pregnancy are significantly higher in affected mothers than in controls, suggesting impairment of cystathionine synthesis or homocysteine remethylation (28) and references cited therein.

Recent studies have identified maternal autoantibodies to the folate receptor in the placenta in a significant number of women with a pregnancy complicated by a neural tube defect (52). A high incidence of neural tube defects is found in murine Folbp1−/− embryos with defective folate transport, even when the diet of the dam is supplemented with folinic acid (63). Folbp1-nullizygous mice show an approximately fourfold increase in plasma total homocyst(e)ine levels as compared with their wild-type littermates (42). In liver and brain tissues of Folbp1−/− mice, the [AdoMet]/[AdoHcy] ratio is maintained, with a trend toward an increase (16). These data reinforce the striking finding that functional folate deficiency actually leads to sparing of AdoMet in at least some tissues, even under conditions of hyperhomocyst(e)inemia. These studies certainly implicate folate deficiency as a potential causative agent for neural tube defects in mice. They are also very important, in that they reveal that severe folate depletion leads to embryonic death, whereas the milder depletion induced when the dam is supplemented with folinic acid leads to embryonic survival and the development of neural tube defects.

However, we still do not know which folate-dependent pathways are required for normal neural tube closure. Is the requirement for remethylation of homocysteine, or for one-car-
bon units for the de novo biosynthesis of purines and pyrimidines, or both or neither? Do the folate pool imbalances associated with some causes of hyperhomocyst(e)inemia exacerbate mild folate deficiency in pregnant women? Studies with the splotch (Pax3) mouse, with a high incidence of neural tube defects, used deoxynthymidine-suppression tests to demonstrate a metabolic deficiency in the supply of folate for thymidylate biosynthesis (18). However, it is not clear whether this mutant mouse is a good surrogate for the etiology of spontaneous neural tube defects in wild-type animals.

None of the models of disrupted one-carbon metabolism that cause hyperhomocyst(e)inemia in mouse models has thus far been associated with a significant increase in the incidence of neural tube defects. That said, spontaneous neural tube defects in the mouse, as in humans, are rarely encountered. The incidence in wild-type mice is estimated to be 0.3 to 4.2 per 1,000 pups (22, 62). Furthermore, severe dietary folate deficiency in mice results in failure to implant, or in embryonic resorption, rather than in viable embryos with neural tube defects (22, 62), similar to the phenotype seen when folate transport is defective due to the absence of Folbp1. Even assuming that an enzyme deficiency was associated with a 10-fold increase in the incidence of neural tube defects, few studies of sufficient statistical power have been conducted to allow detection of such an increase.

An initial approach to such studies would be to determine which enzymes involved in homocysteine and folate metabolism are expressed in mouse embryos during the period of neural tube closure. Cystathionine β-synthase is initially expressed only in liver, skeletal, cardiac, and nervous systems (49), but the studies were performed at E12.5, after neural tube closure is complete. Reverse transcriptase–polymerase chain reaction studies indicate that betaine-homocysteine methyltransferase is complete. Reverse transcriptase–polymerase chain reaction studies were performed at E12.5, after neural tube closure is complete. Reverse transcriptase–polymerase chain reaction studies indicate that betaine-homocysteine methyltransferase is not expressed in either yolk sac or embryonic tissue until E10, when neurulation is nearly complete, so the activity of this enzyme is unlikely to be required for neural tube closure (17). Methionine synthase is expressed in Mtr+/− embryos at E9.5 (61), as is methionine synthase reductase (13). The latter enzyme was shown to be highly expressed in neural tissue as well as in the second and fourth rhombomeres, where migrating neural crest cells are located at this stage of development. Studies do not appear to have been performed on expression of methylene tetrahydrofolate reductase in the embryo, but Mthfr−/− embryos survive until the postnatal period. Because the dam should be able to provide methylene tetrahydrofolate to the developing embryo, methylene tetrahydrofolate reductase may not be required until after birth.

The initial studies on folate deficiency in wild-type mice examined only 300 embryos, and thus lacked the statistical power to detect a modest increase in the incidence of neural tube defects. It would be extremely interesting to compare the incidence of neural tube defects in Mthfr-deficient and Mtrr-deficient mice of the same strain background, because the former have extremely low levels of methylene tetrahydrofolate and reduced cellular [AdoMet]/[AdoHcy] ratios, whereas the latter have elevated or normal levels of methylene tetrahydrofolate and normal to high levels of [AdoMet]/[AdoHcy] in several tissues, including brain. It would also be valuable to examine the effect of supplementation of the dam with various forms of folic acid on the incidence of neural tube defects (e.g., with folic acid or methylene tetrahydrofolate).

The complexity of the etiology of hyperhomocyst(e)inemia suggests that folic acid supplementation alone is unlikely to be a "magic bullet" for all associated pathology in humans. The folate and methionine biochemical pathways are intertwined (see Fig. 1) such that defects in one pathway disturb hemostasis of the other pathway. In designing future studies, the underlying causes of hyperhomocyst(e)inemia should be considered potential confounders. This may prove critical for the development of successful treatments, where a one-size-fits-all approach will likely fail. Although folic acid supplementation might lead to an across-the-board decrease in the levels of homocyst(e)ine in the blood, it is conceivable that imbalances elsewhere in the folate and methionine pathways may yet persist that gave rise to the increase in plasma total homocyst(e)ine in the first place.

**ABBREVIATIONS**

AdoHcy, S-adenosylhomocysteine; AdoMet, S-adenosylmethionine; Hey, homocysteine; Met, methionine; 5-methylTHF, 5-methyltetrahydrofolate; Mtrr−/−, the MtrrGt/Gt(Tfl)[Mgj34By] allele of the Mtrr gene specifying methionine synthase reductase.

**REFERENCES**


10. Dayal S, Devlin AM, McCaw RB, Liu ML, Arning E, Bottiglieri T, Shane B, Faraci FM, and Lentz SR. Cerebral vascular dysfunc-


25. Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kall-
The Many Flavors of Hyperhomocyst(e)inemia


Address reprint requests to: Rowena G. Matthews University of Michigan Life Sciences Institute 210 Washtenaw Avenue Room 4002 Ann Arbor, MI 48109-2216 E-mail: matthew@umich.edu

Date of first submission to ARS Central, June 19, 2007; date of acceptance, June 20, 2007.